medicenna.jpg
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting
April 12, 2021 07:00 ET | Medicenna Therapeutics Corp.
-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages -- Data demonstrate the potential to overcome...
Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting
November 18, 2020 07:00 ET | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Tizona Appoints Christine O’Brien as Chief Executive Officer
September 15, 2020 09:00 ET | Tizona Therapeutics Inc
-- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study – SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 ...
tizona.jpg
Tizona Elects Daniel K. Spiegelman to Its Board of Directors
May 15, 2019 16:00 ET | Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
March 17, 2017 09:07 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™,...
IMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid Year
February 09, 2017 13:39 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and...
Immune Therapeutics Clears Critical Certification Milestone
February 02, 2017 09:40 ET | Immune Therapeutics, Inc.
Immune Therapeutics Receives Approval for Lodonal™ from theDominican Republic’s Ministry of Health and Social Assistance ORLANDO, Fla., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics,...
Immune Therapeutics Redeems $656,250 Convertible Note; Company Actively Working to Strengthen Balance Sheet by Year End
November 15, 2016 09:06 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune...
Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
June 15, 2016 14:46 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., June 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and...